A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
Abstract Introduction Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a long-standing efficacious treatment for psoriasis; however, not all patients sustain a long-term response...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-08-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-020-00436-1 |
id |
doaj-571d40f97d274892abf17391068e582d |
---|---|
record_format |
Article |
spelling |
doaj-571d40f97d274892abf17391068e582d2021-08-22T11:28:49ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722020-08-011051121113510.1007/s13555-020-00436-1A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe PsoriasisEmily K. Haque0Aaminah Azhar1John Corbett2Jillian Frieder3Xuan Wang4Alan Menter5Texas A&M Health Science Center, College of MedicineTexas A&M Health Science Center, College of MedicinePaul L Foster School of Medicine, Texas Tech University Health Science CenterDivision of Dermatology, Baylor University Medical CenterBaylor Research Institute, Baylor University Medical CenterDivision of Dermatology, Baylor University Medical CenterAbstract Introduction Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a long-standing efficacious treatment for psoriasis; however, not all patients sustain a long-term response (LTR) because of a number of factors including antibody production. There is a paucity of studies assessing infliximab efficacy over a period ≥ 5 years. Methods A retrospective cohort chart review of our clinic patients who had undergone ≥ 5 years of treatment with infliximab for chronic plaque psoriasis was performed. The following variables were recorded and analyzed with the Fisher exact test: age, sex, body mass index ([BMI]; normal weight [NW], overweight [OW], obese [OB]), changes in infliximab strength (dose or frequency), concomitant systemic therapy, and side effects. Clinical improvement was assessed by comparing the total body surface area (tBSA) affected by psoriasis before and after treatment. Results There was a significant difference in likelihood of achieving LTR between the NW, OW and OB groups (p = 0.044). Non-normal-weight patients (OW + OB) were significantly more likely to achieve and sustain LTR than NW patients (OR 9.07, p = 0.020). There were no other significant associations for the other evaluated variables. Limitations Patients who began treatment with infliximab before 2009 (prior to the use of the clinic’s electronic medical record) were excluded. The Psoriasis Area and Severity Index (PASI) was not available for this study. Conclusion Surprisingly, patients who are overweight or obese are more likely to obtain long-term clinical benefit in their psoriasis symptoms with infliximab therapy than patients who are normal weight.https://doi.org/10.1007/s13555-020-00436-1Antibodies to infliximabInfliximabLong-term responseMethotrexateObesityPlaque psoriasis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Emily K. Haque Aaminah Azhar John Corbett Jillian Frieder Xuan Wang Alan Menter |
spellingShingle |
Emily K. Haque Aaminah Azhar John Corbett Jillian Frieder Xuan Wang Alan Menter A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis Dermatology and Therapy Antibodies to infliximab Infliximab Long-term response Methotrexate Obesity Plaque psoriasis |
author_facet |
Emily K. Haque Aaminah Azhar John Corbett Jillian Frieder Xuan Wang Alan Menter |
author_sort |
Emily K. Haque |
title |
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis |
title_short |
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis |
title_full |
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis |
title_fullStr |
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis |
title_full_unstemmed |
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis |
title_sort |
real-world evaluation of the long-term safety and efficacy of infliximab in the treatment moderate-to-severe psoriasis |
publisher |
Adis, Springer Healthcare |
series |
Dermatology and Therapy |
issn |
2193-8210 2190-9172 |
publishDate |
2020-08-01 |
description |
Abstract Introduction Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a long-standing efficacious treatment for psoriasis; however, not all patients sustain a long-term response (LTR) because of a number of factors including antibody production. There is a paucity of studies assessing infliximab efficacy over a period ≥ 5 years. Methods A retrospective cohort chart review of our clinic patients who had undergone ≥ 5 years of treatment with infliximab for chronic plaque psoriasis was performed. The following variables were recorded and analyzed with the Fisher exact test: age, sex, body mass index ([BMI]; normal weight [NW], overweight [OW], obese [OB]), changes in infliximab strength (dose or frequency), concomitant systemic therapy, and side effects. Clinical improvement was assessed by comparing the total body surface area (tBSA) affected by psoriasis before and after treatment. Results There was a significant difference in likelihood of achieving LTR between the NW, OW and OB groups (p = 0.044). Non-normal-weight patients (OW + OB) were significantly more likely to achieve and sustain LTR than NW patients (OR 9.07, p = 0.020). There were no other significant associations for the other evaluated variables. Limitations Patients who began treatment with infliximab before 2009 (prior to the use of the clinic’s electronic medical record) were excluded. The Psoriasis Area and Severity Index (PASI) was not available for this study. Conclusion Surprisingly, patients who are overweight or obese are more likely to obtain long-term clinical benefit in their psoriasis symptoms with infliximab therapy than patients who are normal weight. |
topic |
Antibodies to infliximab Infliximab Long-term response Methotrexate Obesity Plaque psoriasis |
url |
https://doi.org/10.1007/s13555-020-00436-1 |
work_keys_str_mv |
AT emilykhaque arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT aaminahazhar arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT johncorbett arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT jillianfrieder arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT xuanwang arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT alanmenter arealworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT emilykhaque realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT aaminahazhar realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT johncorbett realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT jillianfrieder realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT xuanwang realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis AT alanmenter realworldevaluationofthelongtermsafetyandefficacyofinfliximabinthetreatmentmoderatetoseverepsoriasis |
_version_ |
1721199646642012160 |